Patient Perspectives: Using Consistent Terminology for Biomarker and Germline Genetic Testing
A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.
News
Finding Cures Starts Here: The Lymphoma Research Foundation Reaches 25-Year Milestone
LRF celebrates 25 years of innovation and progress with global awareness and fundraising campaign.
Meet the 2020 Career Development Award and Postdoctoral Fellowship Grantees
Projects awarded from this year’s class of CDA and Postdoctoral Fellows include early clinical trials of novel therapies, investigations into the biology of Hodgkin lymphoma and aggressive non-Hodgkin lymphomas, and new mechanisms
for chimeric antigen receptor (CAR) T cell therapy.
Linked By Lymphoma: A Story of Friendship Through the Lymphoma Support Network
Five years ago, Jacqueline Gates and John Groskopf were strangers; they would soon discover they shared a rare similarity that would connect them forever.
U.S. Food and Drug Administration Approves Tafasitamab-cxix (MONJUVI) for Diffuse Large B-cell Lymphoma (DLBCL)
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…
Global Public Relations Executive Joins Lymphoma Research Foundation Board of Directors
Lymphoma Research Foundation Elects Allison+Partners Co-Founder Scott Pansky to Esteemed Board
LRF CEO Meghan Gutierrez Appointed to American Board of Internal Medicine Specialty Board
The American Board of Internal Medicine (ABIM) has ABIM has 12 Specialty Boards - one for all disciplines solely sponsored and administered by ABIM. The Specialty Boards are where the frontline work at the discipline-specific level is done.
U.S. Food and Drug Administration Approves First CAR T Cell Therapy for Mantle Cell Lymphoma: Brexucabtagene Autoleucel (TECARTUS)
Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.
Steven Eichberg Elected Chair of LRF Board of Directors
Eichberg, a Board member since 2019, assumed his new duties from outgoing Chair Michael Werner, whose four-year term concluded on June 30.
LRF Scientific Advisory Board Gains New International Leaders in Lymphoma
The Lymphoma Research Foundation (LRF) welcomes three new members to their elite Scientific Advisory Board (SAB). The new members represent distinct specialties that will contribute to the international impact of the Lymphoma Research Foundation.